These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25139440)

  • 21. Delta-like ligand 4 correlates with endothelial proliferation and vessel maturation in human malignant glioma.
    Li ZQ; Gong LL; Wen ZH; Wang J; Xu CS; Huang XD
    Onkologie; 2012; 35(12):763-8. PubMed ID: 23207622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arsenic Trioxide Suppresses Tumor Growth through Antiangiogenesis via Notch Signaling Blockade in Small-Cell Lung Cancer.
    Yang MH; Chang KJ; Li B; Chen WS
    Biomed Res Int; 2019; 2019():4647252. PubMed ID: 31093499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SIRT1 regulates endothelial Notch signaling in lung cancer.
    Xie M; Liu M; He CS
    PLoS One; 2012; 7(9):e45331. PubMed ID: 23028940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
    Yen WC; Fischer MM; Hynes M; Wu J; Kim E; Beviglia L; Yeung VP; Song X; Kapoun AM; Lewicki J; Gurney A; Simeone DM; Hoey T
    Clin Cancer Res; 2012 Oct; 18(19):5374-86. PubMed ID: 22952347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth.
    Segarra M; Williams CK; Sierra Mde L; Bernardo M; McCormick PJ; Maric D; Regino C; Choyke P; Tosato G
    Blood; 2008 Sep; 112(5):1904-11. PubMed ID: 18577711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delta-like 4/Notch signaling promotes Apc
    Badenes M; Trindade A; Pissarra H; Lopes-da-Costa L; Duarte A
    BMC Cancer; 2017 Jan; 17(1):50. PubMed ID: 28086833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No evidence for a functional role of bi-directional Notch signaling during angiogenesis.
    Liebler SS; Feldner A; Adam MG; Korff T; Augustin HG; Fischer A
    PLoS One; 2012; 7(12):e53074. PubMed ID: 23300864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.
    Djokovic D; Trindade A; Gigante J; Badenes M; Silva L; Liu R; Li X; Gong M; Krasnoperov V; Gill PS; Duarte A
    BMC Cancer; 2010 Nov; 10():641. PubMed ID: 21092311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment.
    Broggini T; Wüstner M; Harms C; Stange L; Blaes J; Thomé C; Harms U; Mueller S; Weiler M; Wick W; Vajkoczy P; Czabanka M
    Cancer Lett; 2016 Oct; 380(2):568-576. PubMed ID: 26297987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
    Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C
    Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
    Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
    BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells.
    Harrington LS; Sainson RC; Williams CK; Taylor JM; Shi W; Li JL; Harris AL
    Microvasc Res; 2008 Mar; 75(2):144-54. PubMed ID: 17692341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
    Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibulin-5 is a prognostic marker that contributes to proliferation and invasion of human glioma cells.
    Sheng XD; Chen H; Wang H; Ding ZB; Xu GZ; Zhang JF; Lu WC; Wu T; Zhao L
    Asian Pac J Cancer Prev; 2015; 16(2):769-73. PubMed ID: 25684523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant expression and association of VEGF and Dll4/Notch pathway molecules under hypoxia in patients with lung cancer.
    Yu S; Sun J; Zhang J; Xu X; Li H; Shan B; Tian T; Wang H; Ma D; Ji C
    Histol Histopathol; 2013 Feb; 28(2):277-84. PubMed ID: 23275310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Vascular Notch Ligands Delta-Like Ligand 4 (DLL4) and Jagged1 (JAG1) Have Opposing Correlations with Microvascularization but a Uniform Prognostic Effect in Primary Glioblastoma: A Preliminary Study.
    Qiu XX; Chen L; Wang CH; Lin ZX; Chen BJ; You N; Chen Y; Wang XF
    World Neurosurg; 2016 Apr; 88():447-458. PubMed ID: 26546995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synaptojanin-2 binding protein stabilizes the Notch ligands DLL1 and DLL4 and inhibits sprouting angiogenesis.
    Adam MG; Berger C; Feldner A; Yang WJ; Wüstehube-Lausch J; Herberich SE; Pinder M; Gesierich S; Hammes HP; Augustin HG; Fischer A
    Circ Res; 2013 Nov; 113(11):1206-18. PubMed ID: 24025447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth.
    Kangsamaksin T; Murtomaki A; Kofler NM; Cuervo H; Chaudhri RA; Tattersall IW; Rosenstiel PE; Shawber CJ; Kitajewski J
    Cancer Discov; 2015 Feb; 5(2):182-97. PubMed ID: 25387766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dll4-containing exosomes induce capillary sprout retraction in a 3D microenvironment.
    Sharghi-Namini S; Tan E; Ong LL; Ge R; Asada HH
    Sci Rep; 2014 Feb; 4():4031. PubMed ID: 24504253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.
    Nandhu MS; Behera P; Bhaskaran V; Longo SL; Barrera-Arenas LM; Sengupta S; Rodriguez-Gil DJ; Chiocca EA; Viapiano MS
    Clin Cancer Res; 2018 Feb; 24(4):821-833. PubMed ID: 29146721
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.